The PROLASTIN-C LIQUID patient support program
Toya, Jesus, and Heather, actual patients
There is help at every step with PROLASTIN DIRECT.
- Insurance verification and help completing your prescription processing
- Pharmacy services, supplies, and delivery to your home or infusion center
- Infusion coordination with a certified alpha-1–trained registered nurse*
- Assistance connecting with a Care Coordinator at AlphaNet
- 24/7 access to expert nurses and pharmacists at 1-833-PHONEA1 (746-6321)
*Service for at-home infusions patients only
My schedule, my alpha-1 journey: Seamless support makes treatment work with my life.
Shipping your medicine, scheduling your infusion, and even administering your infusion are all handled by the PROLASTIN DIRECT program. Whether you will receive PROLASTIN-C LIQUID infusions at home or at an infusion center, PROLASTIN DIRECT will help get your medication shipments to the right location.
Getting started with PROLASTIN-C LIQUID
The PROLASTIN DIRECT Assist Program may help with your copay.
Patients taking PROLASTIN-C LIQUID who have commercial insurance may qualify for a $0 copay through the PROLASTIN DIRECT Assist Program. The program may also help with the cost of the deductible, and can provide up to $10,000 per year every year in financial assistance for eligible patients.
PROLASTIN-C LIQUID: The trusted leader.
The #1 prescribed augmentation therapy, PROLASTIN-C LIQUID has been trusted by patients with alpha-1 and their doctors for more than 35 years.
Looking for more information and insights?
Receive tips for living with alpha-1 and PROLASTIN-C LIQUID updates.
Important Safety Information
PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).
Limitations of Use
- The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials
- Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
- PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established
PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.
Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).
Please see full Prescribing Information for PROLASTIN-C LIQUID.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.